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Gender-Specific Outcomes After
Sirolimus-Eluting Stent Implantation
Emilia Solinas, MD, PHD,* Eugenia Nikolsky, MD, PHD, FACC,* Alexandra J. Lansky, MD, FACC,*
Ajay J. Kirtane, MD, SM,* Marie-Claude Morice, MD, FACC,† Jeffrey J. Popma, MD, FACC,‡
Joachim Schofer, MD,§ Erick Schampaert, MD, Tereza Pucelikova, MD,* Jiro Aoki, MD,*
Martin Fahy, MSC,* George D. Dangas, MD, PHD, FACC,* Jeffrey W. Moses, MD, FACC,*
Donald E. Cutlip, MD, FACC,¶ Martin B. Leon, MD, FACC,* Roxana Mehran, MD, FACC*
New York, New York; Massy, France; Boston, Massachusetts; Hamburg, Germany; and Montreal, Canada
Objectives We examined the impact of gender on outcomes of patients undergoing percutaneous coronary intervention us-
ing sirolimus-eluting stents (SES).
Background Although gender-specific differences in outcome after implantation of bare-metal stents (BMS) have been de-
scribed, there are no data assessing outcomes of women treated with SES.
Methods We performed a patient-level pooled analysis from 4 randomized SES versus BMS trials (RAVEL [Randomized
Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary Revascularization], SIRIUS
[SIRolImUS-coated Bx Velocity balloon expandable stent in the treatment of patients with de novo coronary
artery lesions], E-SIRIUS [Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in
small coronary arteries], and C-SIRIUS [Canadian study of the sirolimus-eluting stent in the treatment of patients
with long de novo lesions in small native coronary arteries]) and analyzed outcomes as a function of gender.
Results Of 1,748 patients, 1,251 were men and 497 were women. A total of 878 patients were randomized to SES (629
men and 249 women), and 870 patients were randomized to BMS (622 men and 248 women). Compared with
men, women were older and more frequently had diabetes mellitus, hypertension, and congestive heart failure.
Although overall clinical outcomes were similar in both genders, treatment with SES was associated with signifi-
cant (p  0.0001) reductions in rates of in-segment binary restenosis both in women (6.3% vs. 43.8%) and in
men (6.4% vs. 35.6%), resulting in a significant reduction in 1-year major adverse cardiac events, driven by a
lower incidence of target lesion revascularization/target vessel revascularization in both genders. By multivari-
able analysis, female gender was not an independent predictor of in-segment binary restenosis or clinical out-
comes regardless of stent type.
Conclusions In this analysis, despite less favorable baseline clinical and angiographic features in women compared with
men, the angiographic and clinical benefits of SES were independent of gender. (J Am Coll Cardiol 2007;50:
2111–6) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.06.056a
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aoronary artery disease is the leading cause of mortality and
orbidity in women in developed countries, and a signifi-
ant proportion of women require coronary revasculariza-
ion (1). Several retrospective studies have focused on
ender-specific differences in outcomes of patients treated
ith percutaneous coronary intervention (PCI). In early
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Manuscript received April 5, 2007; revised manuscript received June 4, 2007,
ccepted June 5, 2007.ngioplasty series, women compared with men had lower
ates of angiographic success, higher incidence of procedural
omplications and in-hospital death, and worse long-term
utcomes (2–4). In the same studies, female gender was
dentified to be an independent predictor of in-hospital
ortality.
Subsequent reports of PCI in women using bare-metal
tents (BMS) have provided conflicting results. Some stud-
es have demonstrated similar rates of restenosis and clinical
vents in women compared with men (2–4). However, in a
arge prospective registry study of 4,374 patients treated
ith BMS, women had lower rates of restenosis at 6-month
ngiographic follow-up compared with those seen in men,
ess frequently required target vessel revascularization
s
o
M
S
o
o
C
c
t
l
t
s
s
p
c
g
p
s
w
V
C
s
o
a
l
t
C
R
E
s
E
p
l
a
P
m
g
o
c
r
C
E
(
m
t
l
n
n
d
T
o
p
n
c
e
Q
g
a
a
f
g
o
s
(
a
a
a

S
q
F
m
t
g
m
a
C
u
r
m
c
M
d
d
2112 Solinas et al. JACC Vol. 50, No. 22, 2007
Ef fect of Gender After SES November 27, 2007:2111–6(TVR) at 1 year, and female
gender was an independent pre-
dictor of freedom from restenosis
(5). In a recent report of 4,284
consecutive patients treated with
PCI (77% received stents), early
outcomes were quite similar be-
tween men and women, whereas
at 3-year follow-up, female gen-
der was associated with a signif-
icant reduction in the hazard of
mortality (6).
Although sirolimus-eluting
stents (SES) are an established
treatment modality in patients
undergoing PCI of native coro-
nary vessels for stable or unstable
angina and/or inducible isch-
emia, no specific gender-based
comparisons have been reported
(7–9). Therefore, we examined
aggregate data from 4 random-
ized, controlled pivotal SES ver-
us BMS trials to assess the association of gender with
utcomes of patients undergoing PCI using SES.
ethods
tudy population. The study represents a pooled analysis
f patients from the RAVEL (Randomized Comparison
f a Sirolimus-Eluting Stent with a Standard Stent for
oronary Revascularization) (7), SIRIUS (SIRolImUS-
oated Bx Velocity balloon expandable stent in the
reatment of patients with de novo coronary artery
esions) (8), E-SIRIUS (Sirolimus-eluting stents for
reatment of patients with long atherosclerotic lesions in
mall coronary arteries) (9), and C-SIRIUS (Canadian
tudy of the sirolimus-eluting stent in the treatment of
atients with long de novo lesions in small native
oronary arteries) trials (10). Outcomes were stratified by
ender and stent type (SES vs. BMS).
The study designs of individual trials have been detailed
reviously. In brief, in all 4 included trials, patients with
table or unstable angina or provoked ischemia and treated
ith PCI were randomly assigned to a sirolimus-eluting Bx
elocity stent (CYPHER, Cordis, a Johnson & Johnson
ompany, Warren, New Jersey) versus a control BMS of a
imilar design for a de novo lesion (stenosis of 51% to 99%
f the luminal diameter by visual assessment on baseline
ngiography) in a native coronary artery. Target lesion
ength was 18 mm in the RAVEL trial, 15 to 30 mm in
he SIRIUS trial, and 15 to 32 mm in the E-SIRIUS and
-SIRIUS trials. Stent diameters were 2.5 to 3.5 mm in the
AVEL and SIRIUS trials and 2.5 to 3.0 mm in the
-SIRIUS and C-SIRIUS trials. The use of more than 1
Abbreviations
and Acronyms
BMS  bare metal stent(s)
CI  confidence interval
DS  diameter stenosis
HR  hazard ratio
MACE  major adverse
cardiac events
MI  myocardial infarction
MLD  minimal luminal
diameter
PCI  percutaneous
coronary intervention
RVD  reference vessel
diameter
SES  sirolimus-eluting
stent(s)
TLR  target lesion
revascularization
TVR  target vessel
revascularizationtent to cover the target lesion was allowed in the SIRIUS, d-SIRIUS, and C-SIRIUS trials. In all included studies,
atients were pre-treated with aspirin (81 to 325 mg) at
east 12 h before PCI, and clopidogrel was administered as
loading dose of 300 mg before or immediately after
CI. Intravenous heparin was administered as boluses to
aintain activated clotting time 250 s. The use of
lycoprotein IIb/IIIa inhibitors was left to the discretion of
perators. After the procedure, treatment with aspirin was
ontinued indefinitely, and the recommended minimal du-
ation of clopidogrel was 8 weeks (RAVEL, E-SIRIUS, and
-SIRIUS) or 12 weeks (SIRIUS).
nd points. Definitions of major adverse cardiac events
MACE) were identical across the trials, including death,
yocardial infarction (MI) (creatine kinase greater than
wice the upper limit of the normal range and an elevated
evel of creatine kinase-MB in the absence or presence of
ew pathological Q waves on the electrocardiogram for
on– or Q-wave MI, respectively), and TVR (any clinically
riven repeat PCI or bypass surgery of the target vessel).
arget lesion revascularization (TLR) was any repeat PCI
f the target lesion or bypass surgery of the target vessel
erformed for recurrent angina, ischemia, or diameter ste-
osis (DS) 70% by quantitative coronary angiography. All
linical end points were adjudicated by independent clinical
vents committees blinded to treatment assignment.
uantitative coronary angiography. Quantitative angio-
raphic measurements were performed by independent
ngiographic core laboratories blinded to the treatment
ssignment (CARDIALYSIS, Rotterdam, the Netherlands,
or the RAVEL trial, and Brigham and Women’s Angio-
raphic Core Laboratory, Boston, Massachusetts, for the
ther trials). Measurements were obtained within the
tented segment (in-stent) and within the lesion segment
the stented segment as well as the margins 5 mm proximal
nd distal to the stent [analysis segment]). Binary restenosis
t angiographic follow-up (6 months in the RAVEL trial,
nd 8 months in the remaining trials) was defined as a DS
50%.
tatistical analysis. Binary variables are presented as fre-
uencies and compared using chi-square statistics or the
isher exact test. Continuous variables are expressed as
ean  standard deviation and compared using 2-sample t
ests. All tests were 2-sided. Kaplan-Meier estimates were
enerated, and comparisons of out-of-hospital events were
ade using the log-rank test.
Multivariable analyses of predictors of clinical outcomes
nd binary angiographic restenosis were performed using
ox proportional hazards regression with stepwise selection
sing entry and exit criteria of p  0.1 and p  0.2,
espectively. The variables chosen for initial entry in the
odels included gender, age, diabetes, hypertension, hyper-
holesterolemia, smoking history, indication for PCI, prior
I, prior PCI, congestive heart failure, chronic kidney
isease, presence of multivessel disease, reference vessel
iameter (RVD), lesion length, Thrombolysis In Myocar-
ial Infarction flow grade 2 or 3, presence of thrombus on
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November 27, 2007:2111–6 Ef fect of Gender After SESaseline angiogram, left anterior descending artery target
essel, and lesion type by American Heart Association/
merican College of Cardiology classification.
Heterogeneity of the treatment effect on binary angio-
raphic restenosis and individual components of MACE
cross the trials was tested using multivariable models with
study  treatment interaction term included, after con-
rolling for baseline patient characteristics. For MACE,
LR, and in-stent restenosis, the p values were 0.80, 0.54,
nd 0.24, respectively, indicating that the treatment effect
as consistent across studies with respect to these 3 outcomes.
esults
tudy patients. Among the 1,748 patients included in the
nalysis, 1,251 (71.6%) were men and 497 (28.4%) were
omen. A total of 878 patients were randomized to SES
629 men [71.6%] and 249 women [28.4%]), and 870
atients were randomized to BMS (622 men [71.5%] and
48 women [28.5%]).
The demographics of the study population stratified by
ender and stent type appear in Table 1. Among patients
ssigned to SES, women were on the average 5 years older,
ad a greater prevalence of comorbidities, and had a higher
requency of angina at rest, but had a lower prevalence of
rior MI or prior myocardial revascularization. Among
atients assigned to BMS, women differed from men in a
imilar fashion, except for rates of prior coronary artery
ypass grafting, which were close in the 2 genders.
As shown in Table 2, among SES-treated patients,
omen had a higher prevalence of single-vessel disease,
hereas other characteristics including RVD and lesion
ength were similar between the 2 genders. Among BMS-
reated patients, left ventricular ejection fraction was slightly
igher in women, and women had a smaller RVD and final
inimal luminal diameters (MLDs), as well as longer
tented segments compared with men.
ngiographic follow-up. When treated with SES, women
nd men had a similar late loss and binary angiographic
estenosis. The patterns of in-stent restenosis and the
aseline Demographic Features Stratified by Gender and Stent Typ
Table 1 Baseline Demographic Features Stratified by Gender a
SES
Men
(n  629)
Women
(n  249) p
Age (mean  SD), yrs 60.3 10.9 65.7 10.9 0
Hypertension, % 59.7 74.2 0
Hypercholesterolemia, % 72.1 67.5 0
Smoking, % 37.8 25.2 0
Diabetes mellitus, % 19.7 28.5 0
Prior myocardial infarction, % 36.1 25.8 0
Prior PCI, % 26.6 13.7 0
Prior coronary artery bypass grafting, % 9.1 3.6 0
Congestive heart failure, % 2.9 7.4 0
Rest angina, % 18.9 29.6 0MS  bare-metal stent; PCI  percutaneous coronary revascularization; SES  sirolimus-eluting stent.ength of restenotic lesions did not differ significantly
etween women and men treated with SES, and focal
n-stent restenosis was the predominant pattern of reste-
osis (Table 3).
When treated with BMS, women compared with men
ad a more prominent late loss and higher rates of angio-
raphic restenosis. However, the patterns of restenosis were
ot related to gender, with the majority of restenoses
emonstrating aggressive patterns (diffuse, proliferative, or
otal occlusion) irrespective of gender (61.4% in men and
8.5% in women, p  0.76).
linical outcomes. Women and men treated with SES
ad similar rates of in-hospital death (0.4% vs. 0%, respec-
ively; p  0.28*), MI (0.8% vs. 2.7%, p  0.11*), stent
hrombosis (0% vs. 0.2%, p  1.00*), and MACE (1.2% vs.
.7%, p  0.21). Similar results were observed among
atients treated with BMS, with close rates of in-hospital
eath, stent thrombosis (no cases in either group), and
VR (0% vs. 0.2%, p  1.00*), though there was a trend
oward a higher frequency of MI among women (2.8% vs.
.1%, p  0.08), mainly due to procedure-related non–
-wave MI (2.8% vs. 1.0%, p  0.05). The Fisher exact
est was used when there were 5 counts in any of the
ategories (indicated by p values with an asterisk [*]).
Clinical outcomes at follow-up are presented in Table 4.
mong patients treated with SES, both genders had a
imilar incidence of 30-day and 1-year MACE. Among
atients treated with BMS, women had significantly higher
ncidence of MI (predominantly non–Q-wave MI) at
-year, but no significant difference in overall MACE.
ES versus BMS in women and men. Among the sub-
roups of women and men, baseline clinical, angiographic,
nd procedural characteristics were well matched between
he 2 randomized treatment arms (SES and BMS). The
nly difference was a higher incidence of prior MI in women
reated with BMS compared with SES.
At angiographic follow-up (Table 3), both genders had
ignificantly larger MLD, smaller DS, lesser late loss, and
ower rates of angiographic restenosis when treated with
ent Type
BMS SES vs. BMS
Men
(n  622)
Women
(n  248) p Value
Men
p Value
Women
p Value
60.52 10.41 65.42 10.53 0.0001 0.75 0.76
57.4 77.8 0.0001 0.45 0.40
70.9 74.2 0.35 0.65 0.11
31.8 25.1 0.06 0.13 1.00
23.5 35.2 0.0007 0.11 0.12
35.4 36.5 0.81 0.85 0.01
23.0 16.6 0.04 0.15 0.38
7.4 7.3 1.00 0.30 0.07
4.2 9.5 0.004 0.22 0.51
18.7 29.2 0.002 0.93 1.00e
nd St
Value
.0001
.0001
.18
.49
.005
.003
.0001
.004
.004
.001
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Ef fect of Gender After SES November 27, 2007:2111–6ES compared with BMS (for women: 86% reduction in
n-lesion binary restenosis and 92% reduction in in-stent
inary restenosis; for men: 82% and 93%, respectively).
ates of aggressive patterns of restenosis were remarkably
ower in both genders treated with SES compared with
MS.
In women, treatment with SES versus BMS was associ-
ted with a trend toward a lower incidence of non–Q-wave
I but similar rates of MACE at 30 days and significantly
ower rates of non–Q-wave MI, TLR, and/or TVR at 1
ear, resulting in a highly significant (63.7%) reduction in
-year MACE (Table 4, Fig. 1B). Treatment with SES in
en was associated with a higher incidence of MI at 30 days
ut not at 1 year. Regardless of gender, there was a
ignificantly lower incidence of TLR and TVR in SES-
reated patients resulting in a 66.7% reduction in 1-year
ACE (Table 4, Fig. 1A).
ultivariable analyses. Female gender was not associated
ith in-segment binary restenosis either among patients
reated with SES (hazard ratio [HR] 0.63, 95% confidence
nterval [CI] 0.25 to 1.53, p  0.31) or BMS (HR 1.35,
5% CI 0.91 to 1.96, p  0.13). Among patients treated
ith SES, independent predictors of in-segment binary
estenosis included diabetes (HR 3.00, 95% CI 1.43 to 6.31,
 0.003) and smaller RVD (HR 5.2, 95% CI 2.12 to 12.5,
ngiographic Features and Procedural Outcomes Stratified by Gend
Table 2 Angiographic Features and Procedural Outcomes Strat
SES
Outcome
Men
(n  627)
Women
(n  247) p Va
Left ventricular ejection fraction
(mean  SD), %
56.6 11.1 57.9 10.6 0.1
Multivessel coronary disease, % 41.6 30.9 0.0
Left anterior descending artery
target vessel
46.9 46.0 0.8
Lesion length (mean SD), mm 13.9 5.6 13.8 5.9 0.8
Baseline RVD (mean SD), mm 2.71 0.45 2.72 0.45 0.9
Baseline MLD (mean SD), mm 0.93 0.36 0.97 0.39 0.1
Baseline percent DS
(mean SD)
65.6 11.6 64.3 12.8 0.1
Final RVD (mean SD), mm 2.77 0.41 2.75 0.42 0.5
Final MLD (mean SD), mm
In-segment 2.27 0.46 2.29 0.45 0.6
In-stent 2.59 0.41 2.57 0.38 0.4
Final percent DS (mean SD)
In-segment 18.1 10.1 16.9 9.2 0.0
In-stent 6.7 8.6 7.3 7.6 0.3
Acute gain (mean SD), mm
In-segment 1.34 0.48 1.32 0.46 0.5
In-stent 1.66 0.43 1.60 0.43 0.0
Final TIMI flow grade 3, % 99.1 99.5 1.0
Stent length (mean SD), mm 20.9 7.1 21.0 7.2 0.8
Use of GP IIb/IIIa receptor
inhibitors, %
44.0 44.6 0.9
Procedure success, % 97.6 98.4 0.6
S  diameter stenosis; GP  glycoprotein; MLD  minimal lumen diameter; RVD  reference v 0.0003). Female gender was not associated with clinical dvents at any time point in patients treated with either SES
r BMS.
iscussion
he main findings of this pooled analysis of the outcomes of
omen and men treated with SES or BMS are as follows:
) the use of SES in this clinical trial population was
ssociated with high rates of procedural success and a low
ncidence of in-hospital and 30-day events in both
enders; 2) when treated with SES, women and men have
ow and similar rates of angiographic restenosis and
-year MACE; 3) gender, per se, was not a predictor of
estenosis or MACE among patients treated with SES or
MS; and 4) treatment with BMS in women compared
ith men was associated with higher rates of angio-
raphic restenosis.
In this analysis, women treated with SES had a worse
aseline clinical profile, including older age and higher
revalence of comorbidities, especially diabetes mellitus that
ight result in higher rates of restenosis. However, angio-
raphic and clinical outcomes were independent of gender
ith the magnitude of treatment benefit of SES over BMS
eing almost identical in both women and men. Both
enders had high rates of procedural success, a low inci-
d Stent Type
by Gender and Stent Type
BMS SES vs. BMS
Men
(n  621)
Women
(n  248) p Value
Men
p Value
Women
p Value
56.3 10.8 59.7 11.1 0.0001 0.65 0.09
39.7 36.7 0.44 0.48 0.18
45.8 48.8 0.45 0.73 0.58
13.9 5.8 13.7 6.2 0.73 0.92 0.95
2.74 0.49 2.66 0.45 0.01 0.34 0.13
0.94 0.37 0.91 0.35 0.36 0.78 0.09
65.7 11.6 65.5 11.4 0.77 0.84 0.30
2.79 0.47 2.69 0.42 0.003 0.35 0.13
2.29 0.47 2.22 0.45 0.056 0.46 0.11
2.59 0.42 2.52 0.40 0.02 0.98 0.17
17.9 9.5 17.6 9.3 0.57 0.81 0.43
7.5 8.6 6.4 8.7 0.12 0.98 0.27
1.35 0.49 1.31 0.44 0.15 0.56 0.73
1.65 0.44 1.60 0.40 0.12 0.87 0.92
88.9 92.7 0.10 0.45 1.00
20.2 6.9 21.4 8.0 0.04 0.10 0.54
42.4 45.7 0.40 0.60 0.85
98.7 96.8 0.08 0.20 0.25
iameter; TIMI  Thrombolysis In Myocardial Infarction; other abbreviations as in Table 1.er an
ified
lue
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November 27, 2007:2111–6 Ef fect of Gender After SEShrombosis regardless of the stent used. This is in contrast
o several previous PCI series in which women compared
ith men had markedly lower rates of procedural success
nd worse in-hospital outcomes including mortality (11–13)
ut in accord with the data from the recent series on 1,166
onsecutive patients treated with drug-eluting stents in
hich procedural success and in-hospital MACE were
imilar for both genders (14).
ngiographic Outcomes at Follow-Up Stratified by Gender and Sten
Table 3 Angiographic Outcomes at Follow-Up Stratified by Gen
SES
Outcome
Men
(n  484)
Women
(n  174) p Value
RVD (mean  SD), mm 2.73 0.42 2.71 0.45 0.63
MLD (mean  SD), mm
In-segment 2.07 0.55 2.12 0.54 0.33
In-stent 2.43 0.54 2.40 0.55 0.57
Percent DS (mean SD)
In-segment 24.5 14.7 22.1 14.4 0.06
In-stent 11.7 15.2 13.0 14.5 0.30
Late loss, mm
In-segment 0.17 0.44 0.15 0.43 0.44
In-stent 0.14 0.42 0.15 0.39 0.87
Binary restenosis rate, %
In-segment 6.4 6.3 1.00
In-stent 2.3 3.4 0.40
Patterns of restenosis, %
Focal 83.3 90.9 1.00
Diffuse 3.3 0.0 1.00
Proliferative 6.7 0.0 1.00
Total occlusion 6.7 9.1 1.00
Length of restenotic lesion
(mean SD), mm
8.8 5.4 8.9 5.4 0.94
bbreviations as in Tables 1 and 2.
linical Outcomes Stratified by Gender and Stent Type
Table 4 Clinical Outcomes Stratified by Gender and Stent Type
SES
Outcome
Men
(n  629)
Women
(n  249) p
At 30 days (cumulative)
Death, n (%) 0 (0.0) 1 (0.4)
Myocardial infarction, n (%) 19 (3.0) 3 (1.2)
Q-wave 5 (0.8) 1 (0.4)
Non–Q-wave 14 (2.2) 2 (0.8)
Target vessel revascularization, n (%) 5 (0.8) 1 (0.4)
Major adverse cardiac events, n (%) 19 (3.0) 4 (1.6)
Stent thrombosis, n (%) 3 (0.5) 1 (0.4)
At 1 year (cumulative)
Death, n (%) 2 (0.3) 2 (0.8)
Myocardial infarction, n (%) 23 (3.7) 6 (2.4)
Q-wave 7 (1.1) 1 (0.4)
Non–Q-wave 16 (2.5) 5 (2.0)
Stent thrombosis, n (%) 4 (0.6) 1 (0.4)
Target lesion revascularization, n (%) 27 (4.3) 10 (4.1)
Target vessel revascularization, n (%) 35 (5.6) 17 (6.9)
Major adverse cardiac events, n (%) 48 (7.7) 20 (8.1)bbreviations as in Table 1.In this analysis, we did not find a significant difference in
ates of angiographic restenosis and associated clinical
vents between men and women treated with SES. This is
n partial agreement with a gender-based analysis from
AXUS-IV trial, which found very similar rates of angio-
raphic restenosis in men and women treated with
aclitaxel-eluting stents (15). However, in TAXUS-IV,
omen compared with men had approximately twice the
e
nd Stent Type
BMS SES vs. BMS
Men
(n  494)
Women
(n  175) p Value
Men
p Value
Women
p Value
2.68 0.45 2.63 0.43 0.22 0.06 0.08
1.55 0.67 1.38 0.68 0.006 0.0001 0.0001
1.62 0.73 1.43 0.74 0.003 0.0001 0.0001
42.9 21.6 47.7 23.5 0.01 0.0001 0.0001
40.1 23.9 45.8 25.4 0.01 0.0001 0.0001
0.73 0.62 0.83 0.67 0.07 0.0001 0.0001
0.95 0.64 1.09 0.70 0.02 0.0001 0.0001
35.6 43.8 0.05 0.0001 0.0001
34.2 43.2 0.03 0.0001 0.0001
38.6 41.4 0.76 0.0001 0.002
39.2 30.0 0.23 0.0001 0.06
13.7 17.1 0.54 0.37 0.20
8.5 11.4 0.47 1.00 1.00
14.7 7.3 15.4 7.8 0.53 0.0001 0.002
BMS SES vs. BMS
Men
(n  622)
Women
(n  248) p Value
Men
p Value
Women
p Value
1 (0.2) 0 (0.0) 0.52 0.31 0.31
8 (1.3) 8 (3.2) 0.06 0.03 0.12
1 (0.2) 0 (0.0) 0.52 0.10 0.31
7 (1.1) 8 (3.2) 0.03 0.12 0.05
2 (0.3) 0 (0.0) 0.37 0.26 0.99
9 (1.4) 8 (3.2) 0.08 0.06 0.002
1 (0.2) 0 (0.0) 0.52 0.32 0.31
3 (0.5) 1 (0.4) 0.87 0.64 0.56
15 (2.4) 15 (6.1) 0.007 0.19 0.04
2 (0.3) 1 (0.4) 0.85 0.09 0.99
13 (2.1) 14 (5.7) 0.006 0.58 0.03
2 (0.3) 3 (1.2) 0.11 0.41 0.31
132 (21.5) 45 (18.3) 0.36 0.0001 0.0001
147 (23.9) 50 (20.4) 0.33 0.0001 0.0001
143 (23.1) 55 (22.3) 0.94 0.0001 0.0001t Typ
der aValue
0.11
0.12
0.52
0.15
0.52
0.23
0.88
0.33
0.34
0.31
0.63
0.67
0.86
0.47
0.87
r
a
p
m
i
w
r
a
c
d
S
S
s
g
g
c
m
t
w
a
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T
s
n
1
s
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e
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1
1
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Ef fect of Gender After SES November 27, 2007:2111–6ate of 1-year TLR (7.6% vs. 3.2%, respectively; p  0.03)
nd TVR (10.8% vs. 5.7%, p  0.03) when treated with a
aclitaxel-eluting stent.
Our study also showed that both genders had a similar
agnitude of treatment effect achieved with SES over BMS
n reducing clinical and angiographic restenosis. When SES
ere used, both women and men had greater than an 80%
eduction in binary angiographic restenosis and greater than
60% reduction in 1-year TLR, TVR, and MACE. In
omplete agreement with data from TAXUS-IV trial, gender
id not predict angiographic restenosis or MACE in either
ES or BMS arm (15).
tudy limitations. This post-hoc analysis was not pre-
pecified, and should thus be considered hypothesis-
enerating. Although the trials included were relatively homo-
eneous with respect to patient selection and treatment
haracteristics, variations in enrollment criteria and treatment
Figure 1 One-Year Survival Free
From MACE in Men and Women
(A) Kaplan-Meier curves of 1-year major adverse cardiac events (MACE)-free sur-
vival in men treated with percutaneous coronary intervention using sirolimus-eluting
stents (SES) versus bare-metal stents (BMS). (B) Kaplan-Meier curves of 1-year
MACE-free survival in women treated with percutaneous coronary intervention
using SES versus BMS.ay have influenced the results. Follow-up medications knowno improve prognosis in patients with coronary artery disease
ere not captured by the database, not allowing more detailed
nalysis of clinical outcomes in relation to gender.
onclusions
his pooled analysis of 4 randomized trials shows that SES
afely and effectively reduce clinical and angiographic reste-
osis in both genders. Both women and men derive similar
-year clinical benefit from SES compared with BMS. Irre-
pective of stent type, female gender was not a predictor of
estenosis or other associated clinical events. These data await
urther confirmation in unselected patients treated with SES.
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